DUSP22 and metabolic dysfunction-associated steatotic liver disease: To probe whether DUSP22 was involved in NAFLD-HCC progression, DUSP22 expression levels were subsequently examined in 8-paired human NAFLD-HCC tumor samples and the paired adjacent normal tissues.